Found: 12
Select item for more details and to access through your institution.
In Vivo Transfer of Intracellular Labels from Locally Implanted Bone Marrow Stromal Cells to Resident Tissue Macrophages.
- Published in:
- PLoS ONE, 2009, v. 4, n. 8, p. 1, doi. 10.1371/journal.pone.0006712
- By:
- Publication type:
- Article
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
- Published in:
- Cytometry. Part B, 2016, v. 90, n. 1, p. 73, doi. 10.1002/cyto.b.21268
- By:
- Publication type:
- Article
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 463, doi. 10.1016/j.clml.2023.03.012
- By:
- Publication type:
- Article
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00782-7
- By:
- Publication type:
- Article
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00665-x
- By:
- Publication type:
- Article
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
- Published in:
- Pediatric Blood & Cancer, 2022, v. 69, n. 8, p. 1, doi. 10.1002/pbc.29602
- By:
- Publication type:
- Article
Proteasome inhibitor‐associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 9, p. E218, doi. 10.1002/ajh.25832
- By:
- Publication type:
- Article
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 12, p. 1159, doi. 10.1002/ajh.23831
- By:
- Publication type:
- Article
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1786, doi. 10.1002/onco.13887
- By:
- Publication type:
- Article
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. 879, doi. 10.1002/onco.13859
- By:
- Publication type:
- Article
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
- Published in:
- Oncologist, 2017, v. 22, n. 11, p. 1347, doi. 10.1634/theoncologist.2017-0229
- By:
- Publication type:
- Article